Filter

511 - 520 of 800 Results

  • Medicare Prescription Drug Plans in 2008 and Key Changes Since 2006: Summary of Findings

    Issue Brief

    This synthesis of key findings from analysis presented in a series of eight Medicare Part D 2008 Data Spotlights describes key features of stand-alone prescription drug plans offered in 2008 and trends since 2006. The synthesis covers a range of topics, including premiums, the coverage gap, benefit design, cost sharing, specialty tiers, formularies, utilization management, the top 10 brand-name prescription drugs, and the availability of low-income subsidy plans. The analysis was conducted jointed by Jack…

  • USA Today/Kaiser Family Foundation/Harvard School of Public Health Survey: The Public on Prescription Drugs and Pharmaceutical Companies

    Poll Finding

    This poll, the third in a series conducted jointly by USA Today and public opinion researchers at the Kaiser Family Foundation and the Harvard School of Public Health, by USA Today, the Kaiser Family Foundation and the Harvard School of Public Health finds Americans greatly value prescription drugs’ potential benefits for their families, but most believe they cost too much money and many struggle to pay for needed medicines. The survey also provides a comprehensive…

  • Medicare and the President’s Fiscal Year 2009 Budget Proposal

    Fact Sheet

    Medicare and the President's Fiscal Year 2009 Budget Proposal This fact sheet summarizes key Medicare-related provisions in the Bush Administration's fiscal year 2009 budget proposal, as well as additional legislation that responds to the Medicare Trustees' "Medicare Funding Warning." Fact Sheet (.pdf)

  • Methodology Appendix to the Medicare Part D 2008 Data Spotlights

    Issue Brief

    The Kaiser Family Foundation has also posted an appendix detailing the methodology used in the Medicare Part D 2008 Data Spotlight series. The series analyzes key aspects of the 2008 Medicare Part D prescription drug plan choices. All of the spotlights in this series were prepared by a team of researchers at Georgetown University, NORC and the Kaiser Family Foundation. Data Spotlight Appendix (.pdf)

  • Medicare Part D 2008 Data Spotlight: Formularies

    Issue Brief

    This Medicare Part D data spotlight examines the formularies (list of covered drugs) of Medicare stand-alone prescription drug plans in 2008, changes since 2006, and differences in how plans cover brand-name and generic drugs. This is one in a series analyzing key aspects of the 2008 Medicare Part D prescription drug plan choices. It analyzes data from the 47 stand-alone prescription drug plans available nationwide using a sample of commonly-used and high-cost prescription drugs. The…

  • Medicare Part D 2008 Data Spotlight: Utilization Management

    Issue Brief

    This Medicare Part D data spotlight examines three common techniques used by Medicare stand-alone prescription drug plans in 2008 to manage enrollees’ use of formulary drugs, such as quantity limits, prior authorization, and step therapy rules. This is one in a series analyzing key aspects of the 2008 Medicare Part D prescription drug plan choices. It analyzes data from the 47 stand-alone prescription drug plans available nationwide using a sample of 169 commonly-used and high-cost…

  • Medicare Part D 2008 Data Spotlight: Specialty Tiers

    Issue Brief

    This Medicare Part D data spotlight focuses on the use of specialty tiers for high-cost and injectible drugs in Medicare Prescription Drug Plans in 2008. It finds that the number of plans with specialty tiers has nearly doubled since 2006. It also looks at the drugs assigned to specialty tiers, the beneficiary cost sharing structure, and policy implications such higher out-of-pocket expenses and selection issues among beneficiaries who evaluate plans based on cost sharing. This…

  • Medicare Part D 2008 Data Spotlight: Benefit Design

    Issue Brief

    This Medicare Part D data spotlight examines the benefit design of Medicare Part D Prescription Drug Plans (PDP) in 2008, focusing on national plans. It shows that in 2008, as in previous years, only about 10 percent of national prescription drug plans offered the defined standard benefit. The spotlight also looks at cost sharing structures, the use of flat dollar copayments, the upward trend in cost sharing for non-preferred drugs, and recent changes in cost…